NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE111200 Query DataSets for GSE111200
Status Public on Mar 08, 2018
Title Integrated genetic and epigenetic analysis of myxofibrosarcoma
Organism Homo sapiens
Experiment type Methylation profiling by array
Summary Myxofibrosarcoma (MFS) is a common adult soft tissue sarcoma characterized by an infiltrative growth pattern and a high local recurrence rate and high propensity for local recurrence. Using 41 MFSs as a discovery set, we underwent whole exome sequencing (N=41), RNA sequencing (N=29), and methylation analysis (N=41). We subsequently performed targeted sequencing of 140 genes in the entire cohort of 99 MFSs to validate the results in the discovery samples. We also combined 17 MFSs data from TCGA to characterize the molecular features of MFS. Fourteen driver genes were identified, including potentially actionable therapeutic targets seen in 37% of cases. There were frequent alterations in p53 signaling (51%; TP53 and MDM2) and cell cycle checkpoint genes (43%; RB1, CDKN2A/CDKN2B, CDK6, and CCND1) genes. Other conceivably actionable driver genes including ATRX, JAK1, NF1, NTRK1 and novel oncogenic BRAF fusion gene were identified and a novel oncogenic BRAF fusion gene, SLC37A3-BRAF, which could potentially be targeted with BRAF inhibitors, and other conceivably actionable driver genes (ATRX, JAK1, NF1, and NTRK1) were identified. Methylation patterns clustered into three subtypes associated with unique combinations of MFS driver mutations. This cluster was also associated with clinical outcomes, and immune cell compositions. Our results provide a valuable genomic resource to enable the design of precision medicine for MFS. Here, based on these analyses, we identified recurrent driver genes, including novel BRAF fusion gene, and novel methylation clusters associated with unique combinations of driver mutations, clinical outcomes, and immune cell compositions.
 
Overall design Bisulphite converted DNA from the 50 samples were hybridised to the Illumina Infinium HumanMethylation450 BeadChip
 
Contributor(s) Ogura K, Hosoda F, Arai Y, Nakamura H, Hama N, Totoki Y, Yoshida A, Nagai M, Kato M, Arakawa E, Mukai W, Rokutan H, Kawai A, Tanaka S, Shibata T
Citation(s) 30018380
Submission date Feb 27, 2018
Last update date Jul 26, 2019
Contact name Koichi Ogura
E-mail(s) ogura-tky@umin.ac.jp
Organization name National Cancer Center
Street address 5-1-1 Tsukiji, Chuo-ku
City Tokyo
ZIP/Postal code 104-0045
Country Japan
 
Platforms (1)
GPL13534 Illumina HumanMethylation450 BeadChip (HumanMethylation450_15017482)
Samples (41)
GSM3025134 MFS_01T
GSM3025135 MFS_03T
GSM3025136 MFS_04T
Relations
BioProject PRJNA436151

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE111200_150903_Dr.Ogura50_All.csv.gz 745.2 Mb (ftp)(http) CSV
GSE111200_RAW.tar 183.1 Mb (http)(custom) TAR
GSE111200_unmethylated_and_methylated_signal.txt.gz 169.4 Mb (ftp)(http) TXT
Processed data included within Sample table
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap